Homology Medicines (DB:35H) - Hisse Senedi Fiyatı, Haberler ve Analizler

35H Stoklara Genel Bakış

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.

Şirket hakkında

35H temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 13.23% oranında artması öngörülüyor

Risk Analizi

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir piyasa değeri yok ( €54M )

+ 1 daha fazla risk

Homology Medicines, Inc. Rakipler

Medigene

XTRA:MDG1

€24.2m

Heidelberg Pharma

XTRA:HPHA

€116.5m

2invest

XTRA:2INV

€59.2m

co.don

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Homology Medicines
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.83
52 Haftanın En Yüksek Seviyesi	US$1.26
52 Haftanın En Düşük Seviyesi	US$0.31
Beta	-0.11
11 Aylık Değişim	5.06%
3 Aylık Değişim	73.64%
1 Yıllık Değişim	4.98%
33 Yıllık Değişim	-89.49%
5 Yıllık Değişim	-96.65%
Halka arzdan bu yana değişim	-94.20%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	35H	DE Biotechs	DE Pazar
7D	3.8%	-3.1%	-1.0%
1Y	5.0%	-15.2%	16.1%

Getiri vs. Endüstri: 35H geçen yıl % -15.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 35H geçen yıl % 16.1 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 35H's price volatile compared to industry and market?
35H volatility
35H Average Weekly Movement	14.2%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

İstikrarlı Hisse Senedi Fiyatı: 35H hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 35H 'nin haftalık oynaklığı ( 14% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	7	n/a	www.homologymedicines.com

Homology Medicines, Inc. Temel Bilgiler Özeti

Homology Medicines'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
35H temel i̇stati̇sti̇kler
Piyasa değeri	€49.80m
Kazançlar(TTM)	-€104.32m
Gelir(TTM)	€1.07m

46.6x

P/S Oranı

-0.5x

F/K Oranı

35H aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
35H gelir tablosu (TTM)
Gelir	US$1.16m
Gelir Maliyeti	US$62.00m
Brüt Kâr	-US$60.85m
Diğer Giderler	US$52.12m
Kazançlar	-US$112.96m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.94
Brüt Marj	-5,263.49%
Net Kâr Marjı	-9,771.71%
Borç/Özkaynak Oranı	0%

35H uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

35H Stoklara Genel Bakış

Ödüller

Risk Analizi

Homology Medicines, Inc. Rakipler

XTRA:MDG1

€24.2m

XTRA:HPHA

€116.5m

XTRA:2INV

€59.2m

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines, Inc. Approves Reduction in Workforce

New major risk - Share price stability

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings released: US$0.50 loss per share (vs US$1.61 profit in 1Q 2022)

Full year 2022 earnings released: US$0.087 loss per share (vs US$1.73 loss in FY 2021)

No longer forecast to breakeven

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Forecast to breakeven in 2022

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

First quarter 2022 earnings released: EPS: US$1.61 (vs US$0.021 loss in 1Q 2021)

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)

Revenue misses expectations

Novartis Elects to Terminate the Collaboration and License Agreement with Homology Medicines, Inc

New 90-day high: €12.09

New 90-day high: €10.86

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (Pku) and Hunter Syndrome (Mps Ii)

New 90-day low: €7.86

New 90-day low: €8.14

Third quarter 2020 earnings released: US$0.62 loss per share

Revenue beats expectations

Homology Medicines, Inc. announced that it expects to receive $60 million in funding from Pfizer Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Biotechnology Select Industry Index

New 90-day low - €8.36

New 90-day low - €8.97

First half earnings released

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Homology Medicines, Inc. Temel Bilgiler Özeti

46.6x

-0.5x

Kazanç ve Gelir